Pharmaceutical Technology
MARCH 21, 2023
Based on the individual contract, these CMOs manufacture small molecules or biological active pharmaceutical ingredients (APIs), as well as packaging material, and are charged with other related functions. Sharp Packaging Services is producing the solid dose of the drug and packaging it.
XTalks
FEBRUARY 7, 2023
HR+/HER2- breast cancer is the most common type of breast cancer, with the National Cancer Institute (NCI) estimating 287,850 new cases of female breast cancer in 2022 alone. Despite decades of advances, people living with pre-treated HR+/HER2- metastatic breast cancer need new treatment options. months vs. 11.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
MARCH 25, 2021
She focuses on news relating to the food industry and writes blogs on recruitment and HR in the life sciences. She also writes informative blogs on topics including drug development, life science company profiles and HR content pertaining to the pharma and biotech industries.
The Pharma Data
DECEMBER 29, 2020
As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. The primary clinical objective of this initial analysis was to determine if there was sufficient efficacy in these patients to warrant continuing the trial (i.e., futility analysis).
The Pharma Data
AUGUST 30, 2021
KEYTRUDA is approved for the treatment of patients with PD-L1-positive, hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative, inoperable or recurrent breast cancer, based on the results of the Phase 3 KEYNOTE-355 trial. months (95% CI, 7.6-11.3) months (95% CI, 5.3-7.5), months [95% CI, 5.4-32.4]
The Pharma Data
SEPTEMBER 7, 2021
This new indication was granted approval based on overall survival (OS) findings from the pivotal Phase 3 KEYNOTE-590 trial. KEYTRUDA plus 5-FU and cisplatin reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; 0.86]; p<0.0001). The median OS was 12.4 months (95% CI, 10.5-14.0) months (95% CI, 8.8-10.8)
pharmaphorum
JUNE 17, 2022
Developed by Pfizer, Paxlovid was granted emergency use authorization (EUA) to treat COVID-19 patients based on the EPIC-HR study which showed it reduced the risk of hospitalization or death by almost 90 percent. Paxlovid consists of two different drugs, nirmatrelvir 150mg tablets co-packaged with ritonavir 100mg tablets.
Expert insights. Personalized for you.
147 
Let's personalize your content